Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2018

View Archived Issues

miRNA551b found as therapeutic target for AML

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Scripps Research Institute presents mu-opioid receptor ligand SR-17018

CSIC Zika virus vaccine shows promise in mouse infection models

Ionis begins phase I/II study of ION-TTR-LRx in healthy subjects and patients with hATTR

New tumor organoid includes microenvironment

Responses seen with blinatumomab monotherapy in relapsed/refractory B-cell non-Hodgkin's lymphoma

Rivaroxaban thromboprophylaxis effective only during treatment period in cancer patients

Quinazoline can serve as a novel core structure in the design of potent BRD4 inhibitors

ASLAN Pharmaceuticals presents phase II data for ASLAN-003 in AML patients

Geranylgeranyl diphosphate synthase inhibitors RAM-2061, RAM-2093 show promise for multiple myeloma

Aimmune Therapeutics submits IND application for AR-201 as treatment of egg allergy

Combination approach revs up beta cell production

Platform could prove broad strategy against emerging viruses

MUC17 and PCNX1 as novel biomarkers of chemotherapy response in breast cancer

Elzonris receives FDA approval for the treatment of blastic plasmacytoid dendritic cell neoplasm

Novartis receives approval in the E.U. for expanded indication for Kisqali

Suglat Tablets approved for additional indication of type 1 diabetes mellitus in Japan

FDA approves Inbrija

FDA grants early approval for Ultomiris for the treatment of adults with PNH

Merck KGaA and Pfizer terminate JAVELIN Ovarian 100 study of avelumab

Phase II TRAXAR study does not meet primary endpoint

Life Science Institute initiates exploratory clinical trial of CL-2020 in epidermolysis bullosa

Novartis reports compounds for treatment of parasitic diseases

Esteve Pharmaceuticals patent reports agents for the treatment of pain

Hemlibra subcutaneous injection approved in Japan for hemophilia A without inhibitors

Chugai receives approval in Japan for Tecentriq for additional dosing in NSCLC

FDA approves IND for anti-GM-CSF monoclonal antibody TJM2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...